Results 271 to 280 of about 328,798 (314)

Interventional oncology in children: Where are we now?

open access: yesJournal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel   +1 more
wiley   +1 more source

The Roles of EDA2R in Ageing and Disease

open access: yesAging Cell, EarlyView.
Elevated expression of the ectodysplasin A2 receptor (EDA2R) has been linked to ageing and disease. We appraise the roles of EDA2R in these processes, exploring mechanisms of action, biomarker potential and therapeutic relevance of EDA2R in multiple contexts. ABSTRACT Ageing is a complex biological process driven, in part, by inflammaging.
Gemma Farrington   +9 more
wiley   +1 more source

Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Over 5000 patients are newly diagnosed with Alopecia areata (AA) in Australia each year. AA severity varies from a single small patch to complete loss of scalp hair, body hair including eyelashes and eyebrows. Approximately 40% of affected individuals experience only a single patch and achieve spontaneous, complete and durable remission within
Daniella Kushnir‐Grinbaum   +19 more
wiley   +1 more source

A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer [PDF]

open access: yes, 2019
Baranski, Thomas   +8 more
core   +1 more source

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO‐NASH Trial

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
This secondary analysis of the MAESTRO‐NASH trial examined the effects of resmetirom in patients with weight loss and/or treated with therapies for T2D. The efficacy of resmetirom was not impacted by background T2DM therapies. Weight loss (≥ 5%) enhanced the effect of resmetirom on multiple MASH endpoints. ABSTRACT Background MAESTRO‐NASH, a randomised,
Mazen Noureddin   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy